274 related articles for article (PubMed ID: 18937615)
21. Androgen deprivation therapy for prostate cancer.
Singer EA; Golijanin DJ; Miyamoto H; Messing EM
Expert Opin Pharmacother; 2008 Feb; 9(2):211-28. PubMed ID: 18201145
[TBL] [Abstract][Full Text] [Related]
22. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.
Saylor PJ; Smith MR
J Natl Compr Canc Netw; 2010 Feb; 8(2):211-23. PubMed ID: 20141678
[TBL] [Abstract][Full Text] [Related]
23. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular risks of androgen deprivation therapy.
Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
[TBL] [Abstract][Full Text] [Related]
25. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry.
Cary KC; Singla N; Cowan JE; Carroll PR; Cooperberg MR
J Urol; 2014 Apr; 191(4):964-70. PubMed ID: 24184370
[TBL] [Abstract][Full Text] [Related]
26. Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.
Gonzalez BD; Jim HS; Donovan KA; Small BJ; Sutton SK; Park J; Lin HY; Spiess PE; Fishman MN; Jacobsen PB
J Urol; 2015 Sep; 194(3):690-5. PubMed ID: 25791402
[TBL] [Abstract][Full Text] [Related]
27. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
28. Treatment of gynecomastia in patients with prostate cancer and androgen deprivation.
Bautista-Vidal C; Barnoiu O; García-Galisteo E; Gómez-Lechuga P; Baena-González V
Actas Urol Esp; 2014; 38(1):34-40. PubMed ID: 23850393
[TBL] [Abstract][Full Text] [Related]
29. Complications of androgen deprivation therapy in men with prostate cancer.
Chen AC; Petrylak DP
Curr Oncol Rep; 2004 May; 6(3):209-15. PubMed ID: 15066232
[TBL] [Abstract][Full Text] [Related]
30. [Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone].
Terrier JE; Mottet N
Prog Urol; 2013 Feb; 23(2):88-95. PubMed ID: 23352300
[TBL] [Abstract][Full Text] [Related]
31. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
32. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Miller K
Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
[TBL] [Abstract][Full Text] [Related]
33. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
Freedland SJ; Eastham J; Shore N
Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
[TBL] [Abstract][Full Text] [Related]
35. Androgen deprivation therapy-associated vasomotor symptoms.
Jones JM; Kohli M; Loprinzi CL
Asian J Androl; 2012 Mar; 14(2):193-7. PubMed ID: 22286861
[TBL] [Abstract][Full Text] [Related]
36. Uncovering the metabolic complications of androgen deprivation therapy in patients with prostate cancer--where do we take it next?
Pinthus JH
J Urol; 2015 Jun; 193(6):1882-3. PubMed ID: 25794833
[No Abstract] [Full Text] [Related]
37. Adverse effects of androgen-deprivation therapy in prostate cancer and their management.
Rhee H; Gunter JH; Heathcote P; Ho K; Stricker P; Corcoran NM; Nelson CC
BJU Int; 2015 Apr; 115 Suppl 5():3-13. PubMed ID: 25327530
[TBL] [Abstract][Full Text] [Related]
38. [Metabolic disorder after androgen deprivation therapy in patients with prostate cancer].
Yuan JQ; Zhang XW; Xu T; Wang XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Aug; 33(4):468-72. PubMed ID: 21906460
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].
Xu PH; Shen YJ; Xiao WJ; Lin GW; Qin XJ; Zhu Y; Dai B; Ye DW
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):418-421. PubMed ID: 31142065
[No Abstract] [Full Text] [Related]
40. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
